TY - JOUR
T1 - Vaccination with Formulation of Nanoparticles Loaded with Leishmania amazonensis Antigens Confers Protection against Experimental Visceral Leishmaniasis in Hamster
AU - González, Marco Antonio Cabrera
AU - Gonçalves, Ana Alice Maia
AU - Ottino, Jennifer
AU - Leite, Jaqueline Costa
AU - Resende, Lucilene Aparecida
AU - Melo-Júnior, Otoni Alves
AU - Silveira, Patrícia
AU - Cardoso, Mariana Santos
AU - Fujiwara, Ricardo Toshio
AU - Bueno, Lilian Lacerda
AU - Santos, Renato Lima
AU - Carvalho, Tatiane Furtado de
AU - Garcia, Giani Martins
AU - Paes, Paulo Ricardo de Oliveira
AU - Galdino, Alexsandro Sobreira
AU - Chávez-Fumagalli, Miguel Angel
AU - Melo, Marília Martins
AU - Silveira-Lemos, Denise
AU - Martins-Filho, Olindo Assis
AU - Dutra, Walderez Ornelas
AU - Mosqueira, Vanessa Carla Furtado
AU - Giunchetti, Rodolfo Cordeiro
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/1
Y1 - 2023/1
N2 - Visceral leishmaniasis (VL) is a fatal disease caused by the protozoa Leishmania infantum for which dogs are the main reservoirs. A vaccine against canine visceral leishmaniasis (CVL) could be an important tool in the control of human and CVL by reducing the infection pressure of L. infantum. Despite the CVL vaccine available on the market, the Brazilian Ministry of Health did not implement the use of it in their control programs. In this sense, there is an urgent need to develop more efficient vaccines. In this study, the association between two polymeric nanoformulations, (poly (D, L-lactic) acid (PLA) polymer) loading Leishmania amazonensis antigens, was evaluated as a potential immunobiological agent against VL using golden hamsters as an experimental model. The results indicated that no significant adverse reactions were observed in animals vaccinated with LAPSmP. LAPSmP presented similar levels of total anti-Leishmania IgG as compared to LAPSmG. The LAPSmP and LAPSmG groups showed an intense reduction in liver and spleen parasitic load by qPCR. The LAPSmP and LAPSmG vaccines showed exceptional results, indicating that they may be promising candidates as a VL vaccine.
AB - Visceral leishmaniasis (VL) is a fatal disease caused by the protozoa Leishmania infantum for which dogs are the main reservoirs. A vaccine against canine visceral leishmaniasis (CVL) could be an important tool in the control of human and CVL by reducing the infection pressure of L. infantum. Despite the CVL vaccine available on the market, the Brazilian Ministry of Health did not implement the use of it in their control programs. In this sense, there is an urgent need to develop more efficient vaccines. In this study, the association between two polymeric nanoformulations, (poly (D, L-lactic) acid (PLA) polymer) loading Leishmania amazonensis antigens, was evaluated as a potential immunobiological agent against VL using golden hamsters as an experimental model. The results indicated that no significant adverse reactions were observed in animals vaccinated with LAPSmP. LAPSmP presented similar levels of total anti-Leishmania IgG as compared to LAPSmG. The LAPSmP and LAPSmG groups showed an intense reduction in liver and spleen parasitic load by qPCR. The LAPSmP and LAPSmG vaccines showed exceptional results, indicating that they may be promising candidates as a VL vaccine.
KW - nanotechnology
KW - vaccine
KW - visceral leishmaniasis
UR - http://www.scopus.com/inward/record.url?scp=85146777513&partnerID=8YFLogxK
U2 - 10.3390/vaccines11010111
DO - 10.3390/vaccines11010111
M3 - Article
AN - SCOPUS:85146777513
SN - 2076-393X
VL - 11
JO - Vaccines
JF - Vaccines
IS - 1
M1 - 111
ER -